Clinical Trials Logo

Clinical Trial Summary

Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.


Clinical Trial Description

Patients with pancreatic cancer suffer from multiple symptoms related to the tumor itself or induced by the chemotherapy. The available supportive therapy is still not able to relief all symptoms that are caused by the malignancy itself as well as by the antineoplastic therapy. Additionally, anorexia and weight loss, that often result in increased morbidity and mortality in this patient population as well as in psycho-social burden and suffering in patients and their relatives, are unmet needs in pancreatic cancer patients. Therapeutic approaches focus on treating the malignancy itself, additional nutritional support and physical examination might prevent patients from further side effects such as sarcopenia. During the last decades a number of appetite-modulating drugs have been under clinical investigation. A number of studies focused on the endocannabinoid system, which is involved amongst others in appetite-modulating, antiemetic, analgesic and anti-inflammatory processes. As dronabinol is already used as magistral formulation, its beneficial effect has often been observed in these patients in the clinical routine, especially in patients with therapy-refractory nausea and emesis. Due to its broad efficacy it might be of benefit for patients suffering from malignancy. Thus, investigators want to evaluate the efficacy of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in advanced pancreatic patients during systemic first-line chemotherapy. However, data on optimal dosage are conflicting yet. In detail, investigators want to study whether dronabinol has a positive influence on quality of life and whether symptoms caused by the tumor or by the chemotherapy itself might be palliated by dronabinol. Beneficial and potential harmful side effects and the personal perception of advanced pancreatic cancer patients will be documented. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03984214
Study type Interventional
Source Arbeitsgemeinschaft medikamentoese Tumortherapie
Contact
Status Active, not recruiting
Phase Phase 3
Start date December 16, 2019
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT04054193 - Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Phase 4
Recruiting NCT04430361 - the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Phase 2
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Completed NCT02285647 - An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant Phase 1
Terminated NCT01874119 - Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma Phase 2
Completed NCT01757210 - A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients N/A
Completed NCT01442376 - Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Phase 3
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Completed NCT01031498 - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Phase 2
Terminated NCT02519842 - Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) Phase 3
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT02909478 - Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Phase 3
Terminated NCT03237611 - Low Dose Aprepitant for Patients Receiving Carboplatin Phase 2
Completed NCT03649230 - Observational Study on the Use of Akynzeo® in Patients Receiving HEC
Not yet recruiting NCT02933099 - Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Phase 3
Completed NCT02557035 - An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting Phase 3
Completed NCT00787566 - Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting Phase 2
Completed NCT06121414 - Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy N/A
Completed NCT04918069 - Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN) Phase 2
Completed NCT05851625 - Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients N/A